TY - JOUR
T1 - NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab
AU - Signoriello, Elisabetta
AU - Signori, Alessio
AU - Lus, Giacomo
AU - Romano, Giuseppe
AU - Marfia, Girolama Alessandra
AU - Landi, Doriana
AU - Napoli, Francesca
AU - D' Amico, Emanuele
AU - Zanghí, Aurora
AU - Di Filippo, Paola Sofia
AU - Caliendo, Daniele
AU - Carotenuto, Antonio
AU - Spiezia, Antonio Luca
AU - Fantozzi, Roberta
AU - Centonze, Diego
AU - Lucchini, Matteo
AU - Mirabella, Massimiliano
AU - Cocco, Eleonora
AU - Frau, Jessica
AU - Maniscalco, Giorgia Teresa
AU - Di Battista, Maria Elena
AU - Foschi, Matteo
AU - Surcinelli, Andrea
AU - Bonavita, Simona
AU - Abbadessa, Gianmarco
AU - Pasquali, Livia
AU - Di Gregorio, Maria
AU - Ferrò, Maria Teresa
AU - Sormani, Maria Pia
AU - Schiavetti, Irene
PY - 2024
Y1 - 2024
KW - High-efficacy disease-modifying therapy (HE DMTs)
KW - Highly active MS patients (HAMS)
KW - Multiple sclerosis
KW - NEDA-3
KW - Natalizumab
KW - Ocrelizumab
KW - High-efficacy disease-modifying therapy (HE DMTs)
KW - Highly active MS patients (HAMS)
KW - Multiple sclerosis
KW - NEDA-3
KW - Natalizumab
KW - Ocrelizumab
UR - http://hdl.handle.net/10807/277598
U2 - 10.1016/j.msard.2024.105594
DO - 10.1016/j.msard.2024.105594
M3 - Article
SN - 2211-0348
VL - 87
SP - N/A-N/A
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
ER -